Silverleafe Capital Partners’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$509K Sell
1,945
-339
-15% -$86.9K 0.14% 65
2026
Q2
$575K Buy
2,284
+2
+0.1% +$430 0.16% 58
2026
Q1
$496K Buy
2,282
+1
+0% +$222 0.15% 61
2025
Q4
$521K Buy
2,281
+1
+0% +$228 0.15% 61
2025
Q3
$528K Buy
2,280
+44
+2% +$8.96K 0.16% 53
2025
Q2
$415K Buy
2,236
+88
+4% +$16.4K 0.14% 54
2025
Q1
$450K Buy
2,148
+56
+3% +$10.9K 0.15% 55
2024
Q4
$372K Hold
2,092
– – 0.12% 79
2024
Q3
$413K Buy
2,092
+2
+0.1% +$373 0.14% 59
2024
Q2
$358K Hold
2,090
– – 0.12% 58
2024
Q1
$381K Hold
2,090
– – 0.15% 50
2023
Q4
$324K Hold
2,090
– – 0.15% 39
2023
Q3
$312K Hold
2,090
– – 0.16% 39
2023
Q2
$282K Hold
2,090
– – 0.17% 42
2023
Q1
$333K Buy
2,090
+17
+0.8% +$2.6K 0.21% 40
2022
Q4
$335K Hold
2,073
– – 0.22% 40
2022
Q3
$278K Hold
2,073
– – 0.18% 51
2022
Q2
$318K Hold
2,073
– – 0.19% 43
2022
Q1
$336K Hold
2,073
– – 0.15% 51
2021
Q4
$281K Hold
2,073
– – 0.1% 74
2021
Q3
$224K Sell
2,073
-12
-0.6% -$1.37K 0.09% 75
2021
Q2
$235K Hold
2,085
– – 0.09% 78
2021
Q1
$226K Buy
2,085
+12
+0.6% +$1.28K 0.09% 82
2020
Q4
$222K Buy
+2,073
New +$199K 0.1% 69
2020
Q3
– Sell
-17,430
Closed -$1.71M – 65
2020
Q2
$1.71M Buy
17,430
+13,583
+353% +$1.2M 1.17% 25
2020
Q1
$293K Buy
3,847
+134
+4% +$11.4K 0.35% 30
2019
Q4
$329K Buy
+3,713
New +$308K 0.19% 56

Other funds holding ABBV

Silverleafe Capital Partners's ABBV Position: Q3 2026 in Review

Silverleafe Capital Partners reduced its AbbVie (ABBV) stake by 15% in Q3 2026, selling an estimated $86.9K and leaving 1,945 shares worth $509K. The position accounts for 0.14% of the portfolio, ranked #65.

Silverleafe Capital Partners first reported a position in ABBV in Q4 2019 and has held it in 27 quarters since. The position peaked at $1.71M in Q2 2020. 246 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Silverleafe Capital Partners held 1,945 shares of AbbVie worth $509K as of Q3 2026.
  • Silverleafe Capital Partners sold 339 AbbVie shares in Q3 2026, an estimated $86.9K.
  • AbbVie made up 0.14% of Silverleafe Capital Partners's portfolio in Q3 2026, its #65 holding.
  • Silverleafe Capital Partners first reported a position in AbbVie in Q4 2019 and has held it in 27 quarters since.
  • Silverleafe Capital Partners's AbbVie position peaked at $1.71M in Q2 2020.
  • 246 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Silverleafe Capital Partners's 13F filing for Q3 2026, filed 2 Oct 2026.